Previous History of Breast Cancer Increases Rates of Pulmonary Embolism and Costs after Total Knee Arthroplasty: An Evaluation of 185,114 Matched Patients

Samuel Rosas; T. David Luo; Alexander H. Jinnah; Alejandro Marquez-Lara; Martin W. Roche; Cynthia L. Emory

doi:10.1055/s-0038-1641155

The Journal of Knee Surgery, Table of Contents

J Knee Surg 2019; 32(04): 337-343
DOI: 10.1055/s-0038-1641155

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Previous History of Breast Cancer Increases Rates of Pulmonary Embolism and Costs after Total Knee Arthroplasty: An Evaluation of 185,114 Matched Patients

Authors

Samuel Rosas

¹Department of Orthopedic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
T. David Luo

¹Department of Orthopedic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Alexander H. Jinnah

¹Department of Orthopedic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Alejandro Marquez-Lara

¹Department of Orthopedic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Martin W. Roche

²Department of Orthopedic Surgery, Holy Cross Orthopedic Institute, Fort Lauderdale, Florida
Cynthia L. Emory

¹Department of Orthopedic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Abstract

Risk factors for adverse events after total knee arthroplasty (TKA) relating to malignancy have not been well studied. Thus, the purpose of this study was to conduct a retrospective case–control outcome and cost analysis after TKA in this population. Patients with a history of breast cancer (BrCa) were identified based on the International Classification of Disease 9th revision codes. An age- and sex-matched cohort was also identified of patients without a history of BrCa. Complications, length of stay, comorbidity burden, and reimbursements were tracked at 90 days. Each cohort comprised 92,557 patients. Length of stay was similar between cohorts (p = 0.627). Comorbidity status and incidence of pulmonary embolism (PE), lower extremity ultrasound, and chest computed tomography (CT) use were higher in patients with a history of BrCa (p < 0.05 for all). Control patients had a lower incidence of acute myocardial infarction (0.14 vs. 0.21%; p < 0.001). Surgical complications were similar. The 90-day reimbursements were greater in patients with a history of BrCa (US$13,990 vs. US$13,033 for controls; p = 0.021). Surgeons should be aware of the increased risk of PE after TKA in patients with a history of BrCa as well as increased 90-day costs, which warrant great attention.

Keywords

total knee arthroplasty - cancer - breast - outcomes - cost

Full Text

References

References
1 Jain NB, Higgins LD, Ozumba D. , et al. Trends in epidemiology of knee arthroplasty in the United States, 1990-2000. Arthritis Rheum 2005; 52 (12) 3928-3933
2 Laucis NC, Chowdhury M, Dasgupta A, Bhattacharyya T. Trend toward high-volume hospitals and the influence on complications in knee and hip arthroplasty. J Bone Joint Surg Am 2016; 98 (09) 707-712
3 Mehrotra C, Remington PL, Naimi TS, Washington W, Miller R. Trends in total knee replacement surgeries and implications for public health, 1990-2000. Public Health Rep 2005; 120 (03) 278-282
4 Choi YJ, Ra HJ. Patient satisfaction after total knee arthroplasty. Knee Surg Relat Res 2016; 28 (01) 1-15
5 Skou ST, Roos EM, Laursen MB. , et al. A randomized, controlled trial of total knee replacement. N Engl J Med 2015; 373 (17) 1597-1606
6 Karam JA, Huang RC, Abraham JA, Parvizi J. Total joint arthroplasty in cancer patients. J Arthroplasty 2015; 30 (05) 758-761
7 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66 (01) 7-30
8 Millstone DB, Perruccio AV, Badley EM, Rampersaud YR. Factors associated with adverse events in inpatient elective spine, knee, and hip orthopaedic surgery. J Bone Joint Surg Am 2017; 99 (16) 1365-1372
9 Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract 2011; 2011: 394740
10 Caine GJ, Stonelake PS, Lip GYH, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4 (06) 465-473
11 Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126 (02) 113-118
12 Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol 2016; 32 (07) 852-862
13 Hopewell JW. Radiation-therapy effects on bone density. Med Pediatr Oncol 2003; 41 (03) 208-211
14 Groenen KH, Pouw MH, Hannink G. , et al. The effect of radiotherapy, and radiotherapy combined with bisphosphonates or RANK ligand inhibitors on bone quality in bone metastases. A systematic review. Radiother Oncol 2016; 119 (02) 194-201
15 Howlader NNA, Krapcho M, Miller D. , et al , eds. SEER Cancer Statistics Review, 1975–2014. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2014/
16 Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67 (01) 7-30
17 Heindel P, Tuchman A, Hsieh PC. , et al. Reoperation rates after single-level lumbar discectomy. Spine 2017; 42 (08) E496-E501
18 Roche MW, Law TY, Triplet JJ, Hubbard ZS, Kurowicki J, Rosas S. Effect of hypoglycemia on the incidence of revision in total knee arthroplasty. J Arthroplasty 2017; 32 (02) 499-502
19 Rosas S, Sabeh KG, Buller LT, Law TY, Roche MW, Hernandez VH. Medical comorbidities impact the episode-of-care reimbursements of total hip arthroplasty. J Arthroplasty 2017; 32 (07) 2082-2087
20 Sabeh KG, Rosas S, Buller LT, Roche MW, Hernandez VH. The impact of discharge disposition on episode-of-care reimbursement after primary total hip arthroplasty. J Arthroplasty 2017; 32 (10) 2969-2973
21 Cardoso F, Costa A, Senkus E. , et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 2017; 28 (01) 16-33
22 Shahi A, Chen AF, Tan TL, Maltenfort MG, Kucukdurmaz F, Parvizi J. The incidence and economic burden of in-hospital venous thromboembolism in the United States. J Arthroplasty 2017; 32 (04) 1063-1066
23 Dasta JF, Pilon D, Mody SH. , et al. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. Thromb Res 2015; 135 (02) 303-310
24 van Erkel AR, van den Hout WB, Pattynama PM. International differences in health care costs in Europe and the United States: do these affect the cost-effectiveness of diagnostic strategies for pulmonary embolism?. Eur Radiol 1999; 9 (09) 1926-1931
25 Lebel B, Lewallen D. Total knee arthroplasty dislocation: incidence, etiology, and management. J Bone Joint Sur Br 2010; 92-B (Supp_II): 323
26 Jethanandani RG, Maloney WJ, Huddleston III JI, Goodman SB, Amanatullah DF. Tibiofemoral dislocation after total knee arthroplasty. J Arthroplasty 2016; 31 (10) 2282-2285
27 Choksi P, Williams M, Clark PM, Van Poznak C. Skeletal manifestations of treatment of breast cancer. Curr Osteoporos Rep 2013; 11 (04) 319-328
28 Hansen M, Kjaer M. Sex hormones and tendon. Adv Exp Med Biol 2016; 920: 139-149
29 Flink BJ, Rivelli SK, Cox EA. , et al. Obstructive sleep apnea and incidence of postoperative delirium after elective knee replacement in the nondemented elderly. Anesthesiology 2012; 116 (04) 788-796
30 Senkus E, Kyriakides S, Ohno S. , et al; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 05) v8-v30
31 Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010; 115 (02) 155-162
32 Lalmohamed A, Vestergaard P, Klop C. , et al. Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med 2012; 172 (16) 1229-1235
33 Molloy IB, Martin BI, Moschetti WE, Jevsevar DS. Effects of the length of stay on the cost of total knee and total hip arthroplasty from 2002 to 2013. J Bone Joint Surg Am 2017; 99 (05) 402-407